Spencer Hauck
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Spencer Hauck has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Jiaoti Huang
Department of Pathology, Duke University School of Medicine, Durham, North Carolina
14 shared publications - Alexandra Lapat Polasko
Department of Urology, Stanford University School of Medicine, Stanford, California
10 shared publications - Amato J. Giaccia
Department of Oncology, University of Oxford, Oxford, UK
10 shared publications - Chun-Lung Chiu
Department of Veterinary Medicine, College of Veterinary Medicine National Pingtung University of Science and Technology Neipu Township Pingtung County Taiwan
10 shared publications - Dalin Zhang
Department of Urology, Stanford University, Stanford, CA 94305, USA
10 shared publications - Donna M. Peehl
Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California
10 shared publications
Latest Publications
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Supplementary Table S2 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Supplementary Table S2 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Primary antibodies used for immunohistochemistry (IHC), immunofluorescence (IF), and western blotting (WB)
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Primary antibodies used for immunohistochemistry (IHC), immunofluorescence (IF), and western blotting (WB)
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Figure S1. The levels of murine serum GAS6 before treatment in the LuCaP 147 PDX model. There were no significant differences in murine serum GAS6 levels among groups detected by ELISA
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Figure S1. The levels of murine serum GAS6 before treatment in the LuCaP 147 PDX model. There were no significant differences in murine serum GAS6 levels among groups detected by ELISA
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Figure S6. IHC staining (continuing Fig. 6A) demonstrates batiraxcept alone or in combination with docetaxel reduced p-ERK1/2 protein levels compared to vehicle-treated controls in intratibial LuCaP 147CR PDX model while total AKT proteins levels were similar. Scale bar = 10 μm.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Figure S6. IHC staining (continuing Fig. 6A) demonstrates batiraxcept alone or in combination with docetaxel reduced p-ERK1/2 protein levels compared to vehicle-treated controls in intratibial LuCaP 147CR PDX model while total AKT proteins levels were similar. Scale bar = 10 μm.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Figure S2. Batiraxcept and docetaxel alone or in combination significantly inhibited bone tumor growth and metastasis in LuCaP mPCa AC PDX models. A-B, Representative images of Masson-Goldner staining and Ku70 IHC of PDX cells in the tibiae of LuCaP 147 (A), and LuCaP 35 (B). Human PCa cells marked by Ku70 were significantly decreased after 30 days of treatment by intraperitoneal injection with batiraxcept (20 mg/kg/QOD, n = 8–9, docetaxel (10 mg/kg/QW, n = 9) or the combination of batiraxcept (20 mg/kg/QOD, n = 9) and docetaxel (10 mg/kg/QW, n = 9) compared to vehicle controls (n = 8,10). C-D, Quantification of the IHC Ku70-positive areas in mouse tibia specimens treated with vehicle, batiraxcept, docetaxel, and batiraxcept + docetaxel in A-B. Fold change: combination batiraxcept and docetaxel (B+D) group set as 1. E, Inhibition of LuCaP 147CR tumor cells metastasis to mouse lung lobes by batiraxcept, docetaxel, and batiraxcept + docetaxel combination therapy. The arrowheads indicate Ku70-positive metastatic tumor nodules in the lung, which metastasized from the mice tibiae. F, Quantification of fold changes (docetaxel group set as 1) of human-specific GAPDH level normalized against universal GAPDH level in different treatment groups for LuCaP 147CR. *, p < 0.05; **, p < 0.01; ***, p < 0.001; NS, p > 0.05 not significant. All scale bar = 50 μm.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Figure S2. Batiraxcept and docetaxel alone or in combination significantly inhibited bone tumor growth and metastasis in LuCaP mPCa AC PDX models. A-B, Representative images of Masson-Goldner staining and Ku70 IHC of PDX cells in the tibiae of LuCaP 147 (A), and LuCaP 35 (B). Human PCa cells marked by Ku70 were significantly decreased after 30 days of treatment by intraperitoneal injection with batiraxcept (20 mg/kg/QOD, n = 8–9, docetaxel (10 mg/kg/QW, n = 9) or the combination of batiraxcept (20 mg/kg/QOD, n = 9) and docetaxel (10 mg/kg/QW, n = 9) compared to vehicle controls (n = 8,10). C-D, Quantification of the IHC Ku70-positive areas in mouse tibia specimens treated with vehicle, batiraxcept, docetaxel, and batiraxcept + docetaxel in A-B. Fold change: combination batiraxcept and docetaxel (B+D) group set as 1. E, Inhibition of LuCaP 147CR tumor cells metastasis to mouse lung lobes by batiraxcept, docetaxel, and batiraxcept + docetaxel combination therapy. The arrowheads indicate Ku70-positive metastatic tumor nodules in the lung, which metastasized from the mice tibiae. F, Quantification of fold changes (docetaxel group set as 1) of human-specific GAPDH level normalized against universal GAPDH level in different treatment groups for LuCaP 147CR. *, p < 0.05; **, p < 0.01; ***, p < 0.001; NS, p > 0.05 not significant. All scale bar = 50 μm.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Data from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Purpose:After failing primary and secondary hormonal therapy, castration-resistant and neuroendocrine prostate cancer metastatic to the bone is invariably lethal, although treatment with docetaxel and carboplatin can modestly improve survival. Therefore, agents targeting biologically relevant pathways in prostate cancer and potentially synergizing with docetaxel and carboplatin in inhibiting bone metastasis growth are urgently needed.Experimental Design:Phosphorylated (activated) AXL expression in human prostate cancer bone metastases was assessed by IHC staining. We evaluated the effects of a novel soluble AXL signaling inhibitor, sAXL (batiraxcept or AVB-S6-500), on tumor growth and lung metastases in prostate cancer patient-derived xenograft models that were implanted intratibially. After injection of LuCaP cells into the tibiae, tumors were treated with batiraxcept and docetaxel or carboplatin alone or in combination, and tumor growth was monitored by serum prostate-specific antigen or bioluminescence. Tumor burden was quantified by human-specific Ku70 staining, and metastasis to the lungs was determined using qPCR. Transcriptomic profiling, Western blotting, and immunohistochemistry were performed to identify treatment-regulated gene and protein profile changes.Results:High AXL phosphorylation in human prostate cancer bone metastases correlated with shortened survival. Batiraxcept alone or in combination with docetaxel or carboplatin significantly suppressed intratibial tumor growth and suppressed metastasis to the lungs through multiple mechanisms, including repression of cancer stemness genes (CD44, ALDH1A1, TACSTD2, and ATXN1) and the PI3K, JAK, MAPK, and E2F1/NUSAP1 signaling pathways.Conclusions:Our study provides a robust preclinical rationale and mechanisms of action for using batiraxcept as a single agent or in combination with docetaxel or carboplatin to treat lethal metastatic prostate cancer.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Purpose:After failing primary and secondary hormonal therapy, castration-resistant and neuroendocrine prostate cancer metastatic to the bone is invariably lethal, although treatment with docetaxel and carboplatin can modestly improve survival. Therefore, agents targeting biologically relevant pathways in prostate cancer and potentially synergizing with docetaxel and carboplatin in inhibiting bone metastasis growth are urgently needed.Experimental Design:Phosphorylated (activated) AXL expression in human prostate cancer bone metastases was assessed by IHC staining. We evaluated the effects of a novel soluble AXL signaling inhibitor, sAXL (batiraxcept or AVB-S6-500), on tumor growth and lung metastases in prostate cancer patient-derived xenograft models that were implanted intratibially. After injection of LuCaP cells into the tibiae, tumors were treated with batiraxcept and docetaxel or carboplatin alone or in combination, and tumor growth was monitored by serum prostate-specific antigen or bioluminescence. Tumor burden was quantified by human-specific Ku70 staining, and metastasis to the lungs was determined using qPCR. Transcriptomic profiling, Western blotting, and immunohistochemistry were performed to identify treatment-regulated gene and protein profile changes.Results:High AXL phosphorylation in human prostate cancer bone metastases correlated with shortened survival. Batiraxcept alone or in combination with docetaxel or carboplatin significantly suppressed intratibial tumor growth and suppressed metastasis to the lungs through multiple mechanisms, including repression of cancer stemness genes (CD44, ALDH1A1, TACSTD2, and ATXN1) and the PI3K, JAK, MAPK, and E2F1/NUSAP1 signaling pathways.Conclusions:Our study provides a robust preclinical rationale and mechanisms of action for using batiraxcept as a single agent or in combination with docetaxel or carboplatin to treat lethal metastatic prostate cancer.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Figure S3. Mouse serum PSA after treatment for 30 days. Batiraxcept and docetaxel as single agents or in combination significanty reduced mouse serum PSA detected by ELISA.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Figure S3. Mouse serum PSA after treatment for 30 days. Batiraxcept and docetaxel as single agents or in combination significanty reduced mouse serum PSA detected by ELISA.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Figure S4. Quantification of bone mineral density in mouse tibia specimen after treatment for 30 days. Batiraxcept and docetaxel as single agents or in combination increased bone mineral density (BMD) of the tibiae to a similar extent as determined by microCT.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Figure S4. Quantification of bone mineral density in mouse tibia specimen after treatment for 30 days. Batiraxcept and docetaxel as single agents or in combination increased bone mineral density (BMD) of the tibiae to a similar extent as determined by microCT.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Figure S5. Mouse body weight change (%) after treatment for 30 days. None of the treatment groups displayed significant differences in body weight, indicating overall low toxicity from batiraxcept and docetaxel at the doses administered.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Figure S5. Mouse body weight change (%) after treatment for 30 days. None of the treatment groups displayed significant differences in body weight, indicating overall low toxicity from batiraxcept and docetaxel at the doses administered.
- 29 January 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (7) , 1346-1358
Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Purpose: After failing primary and secondary hormonal therapy, castration-resistant and neuroendocrine prostate cancer metastatic to the bone is invariably lethal, although treatment with docetaxel and carboplatin can modestly improve survival. Therefore, agents targeting biologically relevant pathways in prostate cancer and potentially synergizing with docetaxel and carboplatin in inhibiting bone metastasis growth are urgently needed. Experimental Design: Phosphorylated (activated) AXL expression in human prostate cancer bone metastases was assessed by IHC staining. We evaluated the effects of a novel soluble AXL signaling inhibitor, sAXL (batiraxcept or AVB-S6-500), on tumor growth and lung metastases in prostate cancer patient-derived xenograft models that were implanted intratibially. After injection of LuCaP cells into the tibiae, tumors were treated with batiraxcept and docetaxel or carboplatin alone or in combination, and tumor growth was monitored by serum prostate-specific antigen or bioluminescence. Tumor burden was quantified by human-specific Ku70 staining, and metastasis to the lungs was determined using qPCR. Transcriptomic profiling, Western blotting, and immunohistochemistry were performed to identify treatment-regulated gene and protein profile changes. Results: High AXL phosphorylation in human prostate cancer bone metastases correlated with shortened survival. Batiraxcept alone or in combination with docetaxel or carboplatin significantly suppressed intratibial tumor growth and suppressed metastasis to the lungs through multiple mechanisms, including repression of cancer stemness genes (CD44, ALDH1A1, TACSTD2, and ATXN1) and the PI3K, JAK, MAPK, and E2F1/NUSAP1 signaling pathways. Conclusions: Our study provides a robust preclinical rationale and mechanisms of action for using batiraxcept as a single agent or in combination with docetaxel or carboplatin to treat lethal metastatic prostate cancer.
- 29 January 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (7) , 1346-1358
Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone
Purpose: After failing primary and secondary hormonal therapy, castration-resistant and neuroendocrine prostate cancer metastatic to the bone is invariably lethal, although treatment with docetaxel and carboplatin can modestly improve survival. Therefore, agents targeting biologically relevant pathways in prostate cancer and potentially synergizing with docetaxel and carboplatin in inhibiting bone metastasis growth are urgently needed. Experimental Design: Phosphorylated (activated) AXL expression in human prostate cancer bone metastases was assessed by IHC staining. We evaluated the effects of a novel soluble AXL signaling inhibitor, sAXL (batiraxcept or AVB-S6-500), on tumor growth and lung metastases in prostate cancer patient-derived xenograft models that were implanted intratibially. After injection of LuCaP cells into the tibiae, tumors were treated with batiraxcept and docetaxel or carboplatin alone or in combination, and tumor growth was monitored by serum prostate-specific antigen or bioluminescence. Tumor burden was quantified by human-specific Ku70 staining, and metastasis to the lungs was determined using qPCR. Transcriptomic profiling, Western blotting, and immunohistochemistry were performed to identify treatment-regulated gene and protein profile changes. Results: High AXL phosphorylation in human prostate cancer bone metastases correlated with shortened survival. Batiraxcept alone or in combination with docetaxel or carboplatin significantly suppressed intratibial tumor growth and suppressed metastasis to the lungs through multiple mechanisms, including repression of cancer stemness genes (CD44, ALDH1A1, TACSTD2, and ATXN1) and the PI3K, JAK, MAPK, and E2F1/NUSAP1 signaling pathways. Conclusions: Our study provides a robust preclinical rationale and mechanisms of action for using batiraxcept as a single agent or in combination with docetaxel or carboplatin to treat lethal metastatic prostate cancer.